Format

Send to

Choose Destination
Transl Oncol. 2019 Apr;12(4):661-668. doi: 10.1016/j.tranon.2019.01.005. Epub 2019 Mar 2.

Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts.

Author information

1
Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany. Electronic address: danijel.sikic@uk-erlangen.de.
2
STRATIFYER Molecular Pathology GmbH, Cologne, Germany. Electronic address: ralph.wirtz@STRATIFYER.de.
3
Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany. Electronic address: sven.wach@uk-erlangen.de.
4
Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. Electronic address: lars@clin.au.dk.
5
Department of Urology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. Electronic address: philipp.erben@medma.uni-heidelberg.de.
6
Department of Urology and Pediatric Urology, University Hospital Ulm, Ulm, Germany. Electronic address: christian.bolenz@uniklinik-ulm.de.
7
Department of Urology, University of Regensburg, Regensburg, Germany. Electronic address: johannes.breyer@ukr.de.
8
Department of Urology, University of Regensburg, Regensburg, Germany. Electronic address: wolfgang.otto@ukr.de.
9
Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: hoadley@med.unc.edu.
10
Department of Urology, Baylor College of Medicine, Houston, TX, USA. Electronic address: slerner@bcm.edu.
11
Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany. Electronic address: markus.eckstein@uk-erlangen.de.
12
Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany. Electronic address: arndt.hartmann@uk-erlangen.de.
13
Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany. Electronic address: bastian.keck@web.de.

Abstract

INTRODUCTION:

Gender-specific differences have led to the androgen receptor (AR) being considered a possible factor in the pathophysiology of urothelial carcinoma of the bladder (UCB), but the exact role remains unclear.

MATERIALS AND METHODS:

The association of AR mRNA expression with clinicopathological features was retrospectively analyzed in two previously described cohorts. The first cohort consisted of 41 patients with all stages of UCB treated at Aarhus University Hospital, Denmark. The second cohort consisted of 323 patients with muscle-invasive bladder cancer (MIBC) accumulated by the Cancer Genome Atlas (TCGA) Research Network.

RESULTS:

AR mRNA expression is significantly higher in non-muscle-invasive bladder cancer (NMIBC) when compared to MIBC (P = .0004), with no relevant changes within the different stages of MIBC. AR mRNA expression was significantly associated with TCGA molecular subtypes (P < .0001). In the total cohort, there was no association between AR expression and gender (P = .23). When analyzed separately, females showed a significantly worse disease-free (P = .03) and overall survival (P = .02) when expressing AR mRNA above median level, while the same was not observed for men. Multivariable Cox's regression analyses revealed AR mRNA expression to be an independent prognostic marker for disease-free survival in women (P = .007).

CONCLUSIONS:

AR mRNA expression is significantly higher in NMIBC than in MIBC, while high AR mRNA expression is associated with worse survival in females with MIBC. Further studies need to investigate the gender-specific role of AR in UCB.

PMID:
30831560
DOI:
10.1016/j.tranon.2019.01.005
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center